Icon Advisers Inc. Co. Takes Position in Glaukos Corporation (GKOS)

Icon Advisers Inc. Co. bought a new position in shares of Glaukos Corporation (NYSE:GKOS) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 43,535 shares of the medical instruments supplier’s stock, valued at approximately $1,805,000. Icon Advisers Inc. Co. owned 0.13% of Glaukos Corporation at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in GKOS. Teachers Advisors LLC increased its stake in shares of Glaukos Corporation by 5.7% during the fourth quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock worth $953,000 after purchasing an additional 1,506 shares during the period. Nationwide Fund Advisors increased its stake in shares of Glaukos Corporation by 749.3% during the first quarter. Nationwide Fund Advisors now owns 89,101 shares of the medical instruments supplier’s stock worth $4,571,000 after purchasing an additional 78,610 shares during the period. Great West Life Assurance Co. Can bought a new position in shares of Glaukos Corporation during the first quarter worth approximately $102,000. American Century Companies Inc. increased its stake in shares of Glaukos Corporation by 2.6% during the first quarter. American Century Companies Inc. now owns 135,082 shares of the medical instruments supplier’s stock worth $6,930,000 after purchasing an additional 3,458 shares during the period. Finally, Comerica Bank bought a new position in shares of Glaukos Corporation during the first quarter worth approximately $1,562,000.

ILLEGAL ACTIVITY NOTICE: “Icon Advisers Inc. Co. Takes Position in Glaukos Corporation (GKOS)” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/09/16/icon-advisers-inc-co-takes-position-in-glaukos-corporation-gkos.html.

Glaukos Corporation (GKOS) opened at 31.40 on Friday. The firm’s 50-day moving average price is $37.87 and its 200-day moving average price is $41.45. The company’s market cap is $1.08 billion. Glaukos Corporation has a 1-year low of $28.72 and a 1-year high of $52.49.

A number of brokerages have recently weighed in on GKOS. Stephens reiterated a “buy” rating and set a $47.00 target price on shares of Glaukos Corporation in a research note on Friday. Piper Jaffray Companies reiterated a “buy” rating and set a $38.00 target price on shares of Glaukos Corporation in a research note on Friday. Stifel Nicolaus reiterated a “buy” rating on shares of Glaukos Corporation in a research note on Thursday. Cantor Fitzgerald restated a “buy” rating and set a $60.00 price objective (up previously from $54.00) on shares of Glaukos Corporation in a research note on Thursday. Finally, BidaskClub upgraded Glaukos Corporation from a “hold” rating to a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $49.86.

In other Glaukos Corporation news, Director Orbimed Advisors Llc sold 580,200 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $38.73, for a total transaction of $22,471,146.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Thomas William Burns sold 73,788 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $41.36, for a total value of $3,051,871.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 980,200 shares of company stock worth $37,900,263. Company insiders own 16.40% of the company’s stock.

Glaukos Corporation Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply